

REMARKS


Claims 1-4, 6 and 8-12 are pending. Claims 1, 2, 4, 6, and 8 have been amended to overcome 112 rejections raised by the Examiner. Specifically, the terms "solvates," "esters," "polymorphs," "prodrugs" and "metabolites" have been deleted from the claims. The term "prophylaxis" has also been deleted from the claims. The limitations of claims 5 and 7 have been incorporated into claims 4 and 6, respectively. Claim 2 has been amended by adding "and" before the last member of the list in that claim. All pending rejections and objections are believed to have been overcome thereby.

The Examiner has further noted that the Oath and Declaration are objected to for failing to include the signature of inventor Anita Mehta. Applicants respectfully submit a copy of the Declaration and Power of Attorney forwarded to the USPTO on February 24, 2006 which contains the signature of applicant Anita Mehta.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

By: 
George E. Heibel
Reg. No. 42,648

Date: November 20, 2007

Correspondence Address:

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540

Telephone: (609) 720-5334
Facsimile: (609) 514-9779